

## EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	2762	SAHA	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L2	822196	transport	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L3	24	L1 same L2	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L4	1939	sodium near4 transport	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L5	11571	hydroxamic	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L6	14211	hydroxam\$	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L7	0	L4 same L6	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L8	0	L4 same L5	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L9	158756	lung	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L10	767	trichostatin	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L11	446	L10 and L9	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58

## EAST Search History

L12	822196	transport	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L13	1789	hydroxyamide	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L14	90233	(asthma or bronchitis or COPD or cystic adj fibrosis)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L15	2	L14 near20 L13	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L16	2	L14 same L13	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L17	116	oxyamide	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L18	1	L4 and L17	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L19	206	L10 and L14	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L20	0	L10 near 10123	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58

## EAST Search History

L21	75	US-6147224-\$.DID. OR US-6124495-\$. DID. OR US-6110970-\$.DID. OR US-6110955-\$.DID. OR US-6110697-\$. DID. OR US-6083984-\$.DID. OR US-6071923-\$.DID. OR US-6068987-\$. DID. OR US-6060510-\$.DID. OR US-6046237-\$.DID. OR US-6043389-\$. DID. OR US-6037367-\$.DID. OR US-6030993-\$.DID. OR US-6004988-\$. DID. OR US-6001877-\$.DID. OR US-5998654-\$.DID. OR US-5986131-\$. DID. OR US-5968979-\$.DID. OR US-5932606-\$.DID. OR US-5910606-\$. DID. OR US-5910508-\$.DID. OR US-5908868-\$.DID. OR US-5891737-\$. DID. OR US-5883124-\$.DID. OR US-5804601-\$.DID. OR US-5795914-\$. DID. OR US-5753704-\$.DID. OR US-5710178-\$.DID. OR US-5705167-\$. DID. OR US-5696162-\$.DID. OR US-5688819-\$.DID. OR US-5677320-\$. DID. OR US-5672746-\$.DID. OR US-5643949-\$.DID. OR US-5607978-\$. DID. OR US-5602135-\$.DID. OR US-5547988-\$.DID. OR US-5541155-\$. DID. OR US-5525629-\$.DID. OR US-5486540-\$.DID.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L22	45878	hydroxylamine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L23	0	L10 near10 L14	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L24	14309	hydroxam\$ or hydroxamide or oxyamide	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58

## EAST Search History

L25	76	US-4564476-\$.DID. OR US-4545984-\$. DID. OR US-4534979-\$.DID. OR US-4505930-\$.DID. OR US-4504494-\$. DID. OR US-4472430-\$.DID. OR US-4440940-\$.DID. OR US-4439443-\$. DID. OR US-4388459-\$.DID. OR US-4371614-\$.DID. OR US-4355168-\$. DID. OR US-4335054-\$.DID. OR US-4309407-\$.DID. OR US-4309357-\$. DID. OR US-4288253-\$.DID. OR US-4258057-\$.DID. OR US-4211783-\$. DID. OR US-4193931-\$.DID. OR US-4188338-\$.DID. OR US-4171318-\$. DID. OR US-4130653-\$.DID. OR US-4127723-\$.DID. OR US-4127722-\$. DID. OR US-4116975-\$.DID. OR US-4113858-\$.DID. OR US-4081476-\$. DID. OR US-4061656-\$.DID. OR US-4048332-\$.DID. OR US-4044149-\$. DID. OR US-4024182-\$.DID. OR US-4011339-\$.DID. OR US-3984440-\$. DID. OR US-3978100-\$.DID. OR US-3909353-\$.DID. OR US-3886278-\$. DID. OR US-3781314-\$.DID. OR US-3755604-\$.DID. OR US-3687955-\$. DID. OR US-3674884-\$.DID.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L26	8	US-3624127-\$.DID. OR US-3551574-\$. DID. OR US-3479396-\$.DID. OR US-2840586-\$.DID. OR US-2680755-\$. DID. OR US-6495719-\$.DID.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58

## EAST Search History

L27	76	US-5475022-\$.DID. OR US-5466718-\$.DID. OR US-5420160-\$.DID. OR US-5385942-\$.DID. OR US-5369108-\$.DID. OR US-5320833-\$.DID. OR US-5272180-\$.DID. OR US-5264424-\$.DID. OR US-5246955-\$.DID. OR US-5244922-\$.DID. OR US-5235068-\$.DID. OR US-5141959-\$.DID. OR US-5112846-\$.DID. OR US-5091569-\$.DID. OR US-5089524-\$.DID. OR US-5084214-\$.DID. OR US-5075330-\$.DID. OR US-5064860-\$.DID. OR US-5028629-\$.DID. OR US-4985436-\$.DID. OR US-4981865-\$.DID. OR US-4950467-\$.DID. OR US-4833257-\$.DID. OR US-4820828-\$.DID. OR US-4791133-\$.DID. OR US-4753934-\$.DID. OR US-4731382-\$.DID. OR US-4722939-\$.DID. OR US-4709076-\$.DID. OR US-4699920-\$.DID. OR US-4638011-\$.DID. OR US-4623661-\$.DID. OR US-4621099-\$.DID. OR US-4619945-\$.DID. OR US-4608390-\$.DID. OR US-4607053-\$.DID. OR US-4605669-\$.DID. OR US-4604407-\$.DID.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L28	2	("20030195257").PN.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/08/06 05:58
L29	236	L21 or L27 or L25 or L28 or L26	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L30	35	L29 and L24	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L31	14067	leukotriene	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L32	0	L4 near10 L31	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L33	2762	SAHA	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58

## EAST Search History

L34	2762	l7same L33	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L35	0	L14 near10 L33	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L36	12218	lipox\$	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L37	14067	leukotriene	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L38	51	L14 same L33	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L39	0	L38 and L36	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L40	0	L38 and L37	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L41	296	L14 and L33	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L42	3245	L10 or L33	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L43	205	560/312.ccls.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L44	21536	L37 or L36	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L45	24723	L42 or L44	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58

## EAST Search History

L46	0	L14 near20 L33	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L47	767	trichostatin	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L48	2762	SAHA	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L49	3245	L47 or L48	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L50	1	L42 same L44	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L51	2	"4731382".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L52	12218	lipox\$	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L53	14067	leukotriene	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L54	21536	L53 or L52	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L55	11571	hydroxamic	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L56	1939	sodium near4 transport	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L57	27	L56 and L55	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58

## EAST Search History

L58	3	"2002055688"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L59	14067	leukotriene	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L60	69	L56 and L59	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L61	116	oxyamide	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L62	90233	(asthma or bronchitis or COPD or cystic adj fibrosis)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 11:06
L63	23	L61 and L62	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L64	2	"5028629".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L65	26	"0208379"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L66	58	L49 and L54	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L67	0	L62 near20 L48	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L68	116	oxyamide	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L69	8	US-3624127-\$.DID. OR US-3551574-\$. DID. OR US-3479396-\$.DID. OR US-2840586-\$.DID. OR US-2680755-\$. DID. OR US-6495719-\$.DID.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58



## EAST Search History

L70	14309	hydroxam\$ or hydroxamide or oxyamide	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L71	2	("20030195257").PN.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/08/06 05:58
L72	76	US-5475022-\$.DID. OR US-5466718-\$.DID. OR US-5420160-\$.DID. OR US-5385942-\$.DID. OR US-5369108-\$.DID. OR US-5320833-\$.DID. OR US-5272180-\$.DID. OR US-5264424-\$.DID. OR US-5246955-\$.DID. OR US-5244922-\$.DID. OR US-5235068-\$.DID. OR US-5141959-\$.DID. OR US-5112846-\$.DID. OR US-5091569-\$.DID. OR US-5089524-\$.DID. OR US-5084214-\$.DID. OR US-5075330-\$.DID. OR US-5064860-\$.DID. OR US-5028629-\$.DID. OR US-4985436-\$.DID. OR US-4981865-\$.DID. OR US-4950467-\$.DID. OR US-4833257-\$.DID. OR US-4820828-\$.DID. OR US-4791133-\$.DID. OR US-4753934-\$.DID. OR US-4731382-\$.DID. OR US-4722939-\$.DID. OR US-4709076-\$.DID. OR US-4699920-\$.DID. OR US-4638011-\$.DID. OR US-4623661-\$.DID. OR US-4621099-\$.DID. OR US-4619945-\$.DID. OR US-4608390-\$.DID. OR US-4607053-\$.DID. OR US-4605669-\$.DID. OR US-4604407-\$.DID.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58

## EAST Search History

L73	76	US-4564476-\$.DID. OR US-4545984-\$.DID. OR US-4534979-\$.DID. OR US-4505930-\$.DID. OR US-4504494-\$.DID. OR US-4472430-\$.DID. OR US-4440940-\$.DID. OR US-4439443-\$.DID. OR US-4388459-\$.DID. OR US-4371614-\$.DID. OR US-4355168-\$.DID. OR US-4335054-\$.DID. OR US-4309407-\$.DID. OR US-4309357-\$.DID. OR US-4288253-\$.DID. OR US-4258057-\$.DID. OR US-4211783-\$.DID. OR US-4193931-\$.DID. OR US-4188338-\$.DID. OR US-4171318-\$.DID. OR US-4130653-\$.DID. OR US-4127723-\$.DID. OR US-4127722-\$.DID. OR US-4116975-\$.DID. OR US-4113858-\$.DID. OR US-4081476-\$.DID. OR US-4061656-\$.DID. OR US-4048332-\$.DID. OR US-4044149-\$.DID. OR US-4024182-\$.DID. OR US-4011339-\$.DID. OR US-3984440-\$.DID. OR US-3978100-\$.DID. OR US-3909353-\$.DID. OR US-3886278-\$.DID. OR US-3781314-\$.DID. OR US-3755604-\$.DID. OR US-3687955-\$.DID. OR US-3674884-\$.DID.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L74	75	US-6147224-\$.DID. OR US-6124495-\$.DID. OR US-6110970-\$.DID. OR US-6110955-\$.DID. OR US-6110697-\$.DID. OR US-6083984-\$.DID. OR US-6071923-\$.DID. OR US-6068987-\$.DID. OR US-6060510-\$.DID. OR US-6046237-\$.DID. OR US-6043389-\$.DID. OR US-6037367-\$.DID. OR US-6030993-\$.DID. OR US-6004988-\$.DID. OR US-6001877-\$.DID. OR US-5998654-\$.DID. OR US-5986131-\$.DID. OR US-5968979-\$.DID. OR US-5932606-\$.DID. OR US-5910606-\$.DID. OR US-5910508-\$.DID. OR US-5908868-\$.DID. OR US-5891737-\$.DID. OR US-5883124-\$.DID. OR US-5804601-\$.DID. OR US-5795914-\$.DID. OR US-5753704-\$.DID. OR US-5710178-\$.DID. OR US-5705167-\$.DID. OR US-5696162-\$.DID. OR US-5688819-\$.DID. OR US-5677320-\$.DID. OR US-5672746-\$.DID. OR US-5643949-\$.DID. OR US-5607978-\$.DID. OR US-5602135-\$.DID. OR US-5547988-\$.DID. OR US-5541155-\$.DID. OR US-5525629-\$.DID. OR US-5486540-\$.DID.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58

## EAST Search History

L75	236	L74 or L72 or L73 or L71 or L69	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L76	35	L75 and L70	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L77	1	L49 same L54	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L78	175	oxamflatin	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L79	1789	hydroxyamide	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L80	822196	transport	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L81	296	L62 and L48	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L82	2	L62 same L79	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L83	14211	hydroxam\$	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L84	0	L56 same L83	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L85	24723	L49 or L54	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L86	205	560/312.ccls.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58

## EAST Search History

L87	206	L47 and L62	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L88	0	L47 near10 L62	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L89	0	L56 same L55	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L90	0	L62 near10 L48	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L91	0	L47 near 10I23	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L92	51	L62 same L48	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L93	0	L92 and L53	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L94	1	L56 and L86	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L95	158756	lung	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L96	446	L47 and L95	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L97	2762	l7same L48	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L98	0	L92 and L52	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58

## EAST Search History

L99	2	L62 near20 L79	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L100	1	L56 and L68	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L101	45878	hydroxylamine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L102	0	L56 near10 L59	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L103	1	L4 and L43	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L104	33	L4 and L6	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L105	2	L4 same L33	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L106	17	L17 and L12	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L107	27	L4 and L5	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L108	39	L10 same L9	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L109	2	"5534654" .pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L110	116	oxyamide	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58

## EAST Search History

L111	23	L110 and L14	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L112	21	L14 same L22	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L113	8	L10 same L14	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L114	3	L14 near10 L22	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L115	3	"2002055688"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L116	2	L14 near10 L13	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L117	69	L4 and L31	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L118	4	L14 near20 L22	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L119	2	"20020055688"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L120	26	"0208379"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L121	5	L4 same L31	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L122	21	L14 and L30	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58

## EAST Search History

L123	2	"4731382".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L124	2	"5028629".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L125	58	L42 and L44	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L126	2	L56 same L48	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L127	17	L68 and L80	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L128	2	"5534654" .pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L129	8	L47 same L62	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:58
L130	21	L62 same L101	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:59
L131	21	L62 and L76	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:59
L132	2	L62 near10 L79	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:59
L133	4	L62 near20 L101	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:59
L134	2	"20020055688"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:59

## EAST Search History

L135	5	L56 same L59	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:59
L136	33	L56 and L83	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:59
L137	3	L62 near10 L101	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:59
L138	39	L47 same L95	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:59
L139	259	L14 and L13	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:59
L140	175	oxamflatin	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:59
L141	259	L62 and L79	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:59
L142	79	L1 same L9	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 05:59
L143	77	I5 same I53	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 06:11
L144	201383	lung or asthma	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 06:59
L145	70	I143 and I144	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 06:11
L146	8242	COPD	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 07:00



## EAST Search History

L147	222	I37 same I146	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 07:00
L148	15	I37 near10 I146	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 10:45
L149	548	(514/575).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/08/06 10:46
L150	148	I62 and I149	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 11:00
L151	5	"9912899"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 11:00
L152	7	((asthma or bronchitis or COPD or cystic adj fibrosis) and (SAHA or trichostatin)).clm.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/08/06 11:07

NEWS 14 MAY 14 RDISCLOSURE on STN Easy enhanced with new search and display fields  
 NEWS 15 MAY 21 BIOSIS reloaded and enhanced with archival data  
 NEWS 16 MAY 21 TOXCENTER enhanced with BIOSIS reload  
 NEWS 17 MAY 21 CA/Capplus enhanced with additional kind codes for German patents  
 NEWS 18 MAY 22 CA/Capplus enhanced with IPC reclassification in Japanese patents  
 NEWS 19 JUN 27 CA/Capplus enhanced with pre-1967 CAS Registry Numbers  
 NEWS 20 JUN 29 STN Viewer now available  
 NEWS 21 JUN 29 STN Express, Version 8.2, now available  
 NEWS 22 JUL 02 LEMBASE coverage updated  
 NEWS 23 JUL 02 LMEDLINE coverage updated  
 NEWS 24 JUL 02 SCISEARCH enhanced with complete author names  
 NEWS 25 JUL 02 CHEMCATS accession numbers revised  
 NEWS 26 JUL 02 CA/Capplus enhanced with utility model patents from China  
 NEWS 27 JUL 16 Capplus enhanced with French and German abstracts  
 NEWS 28 JUL 18 CA/Capplus patent coverage enhanced  
 NEWS 29 JUL 26 USPATFULL/USPAT2 enhanced with IPC reclassification  
 NEWS 30 JUL 30 USGENE now available on STN

NEWS EXPRESS 29 JUNE 2007: CURRENT WINDOWS VERSION IS V8.2,  
 CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
 AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
 NEWS LOGIN Welcome Banner and News Items  
 NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 10:02:57 ON 06 AUG 2007

=> file caplus		
COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CAPLUS' ENTERED AT 10:03:17 ON 06 AUG 2007  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 Aug 2007 VOL 147 ISS 7  
 FILE LAST UPDATED: 3 Aug 2007 (20070803/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.  
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> copd and asthma and (cystic fibrosis) and bronchitis

- 3342 COPD
- 17 COPDS
- 3356 COPD
- (COPD OR COPDS)
- 35881 ASTHMA
- 22 ASTHMAS
- 35889 ASTHMA
- (ASTHMA OR ASTHMAS)
- 16731 CYSTIC
- 1 CYSTICS
- 16732 CYSTIC
- (CYSTIC OR CYSTICS)
- 38199 FIBROSIS
- 1 FIBROSISES
- 38199 FIBROSIS
- (FIBROSIS OR FIBROSISES)
- 12689 CYSTIC FIBROSIS
- (CYSTIC(W) FIBROSIS)
- 6450 BRONCHITIS
- 1 BRONCHITISES
- 6451 BRONCHITIS
- (BRONCHITIS OR BRONCHITISES)

L1 35 COPD AND ASTHMA AND (CYSTIC FIBROSIS) AND BRONCHITIS

=> lipoxxygenase or leukotriene

- 17728 LIPOXYGENASE
- 1535 LIPOXYGENASES
- 17969 LIPOXYGENASE
- (LIPOXYGENASE OR LIPOXYGENASES)
- 14523 LEUKOTRIENE
- 8056 LEUKOTRIENES
- 16744 LEUKOTRIENE
- (LEUKOTRIENE OR LEUKOTRIENES)

L2 30339 LIPOXYGENASE OR LEUKOTRIENE

=> l1 and l2

L3 10 L1 AND L2

=> d l3 5-10 ti

L3 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

TI Treatment of respiratory and lung diseases with antisense oligonucleotides and a bronchodilating agent

L3 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

TI Treatment of respiratory and lung diseases with antisense oligonucleotides and a bronchodilating agent

L3 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

TI Preparation of thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl- acid amide derivatives as inhibitors of phosphodiesterase IV isozymes

L3 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

TI Preparation of nicotinamide biaryl derivatives as inhibitors of PDE4 isozymes

L3 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

TI LTB4 antagonism

L3 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN  
TI Low-adenosine antisense oligonucleotide agents, compositions, kits and  
treatments for respiratory disorders

=> diene

69783 DIENE  
24296 DIENES  
L4 82863 DIENE  
(DIENE OR DIENES)

=> 13 and 14

L5 0 L3 AND L4

=> 12 and 14

L6 .226 L2 AND L4


=> d 13 8-10 ti fbib abs

L3 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN  
TI Preparation of nicotinamide biaryl derivatives as inhibitors of PDE4  
isozymes  
AN 2002:594822 CAPLUS  
DN 137:154857  
TI Preparation of nicotinamide biaryl derivatives as inhibitors of PDE4  
isozymes  
IN Chambers, Robert James; Magee, Thomas Victor; Marfat, Anthony  
PA Pfizer Products Inc., USA  
SO PCT Int. Appl., 224 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002060875	A1	20020808	WO 2001-IB2341	20011206
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2001-265492P	P 20010131
CA	2436535	A1	20020808	CA 2001-2436535	20011206
				US 2001-265492P	P 20010131
				WO 2001-IB2341	W 20011206
AU	2002220966	A1	20020812	AU 2002-220966	20011206
				US 2001-265492P	P 20010131
				WO 2001-IB2341	W 20011206
EP	1355884	A1	20031029	EP 2001-273556	20011206
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				US 2001-265492P	P 20010131
				WO 2001-IB2341	W 20011206
EE	200300360	A	20031215	EE 2003-360	20011206
				US 2001-265492P	P 20010131
				WO 2001-IB2341	W 20011206
BR	2001016852	A	20040225	BR 2001-16852	20011206
				US 2001-265492P	P 20010131
				WO 2001-IB2341	W 20011206

HU 200400637	A2	20040628	HU 2004-637		20011206
			US 2001-265492P	P	20010131
			WO 2001-IB2341	W	20011206
JP 2004520386	T	20040708	JP 2002-561026		20011206
			US 2001-265492P	P	20010131
			WO 2001-IB2341	W	20011206
CN 1518542	A	20040804	CN 2001-823071		20011206
			US 2001-265492P	P	20010131
NZ 526453	A	20050128	NZ 2001-526453		20011206
			US 2001-265492P	P	20010131
			WO 2001-IB2341	W	20011206
US 2002193612	A1	20021219	US 2002-62813		20020131
US 6649633	B2	20031118			
			US 2001-265492P	P	20010131
IN 2003MN00608	A	20050318	IN 2003-MN608		20030617
			US 2001-265492P	P	20010131
			WO 2001-IB2341	W	20011206
ZA 2003004894	A	20040624	ZA 2003-4894		20030624
			US 2001-265492P	P	20010131
US 2004048903	A1	20040311	US 2003-613988		20030702
US 6953810	B2	20051011			
			US 2001-265492P	P	20010131
			US 2002-62813	A3	20020131
BG 108038	A	20040730	BG 2003-108038		20030728
			US 2001-265492P	P	20010131
			WO 2001-IB2341	W	20011206
NO 2003003397	A	20030919	NO 2003-3397		20030730
			US 2001-265492P	P	20010131
			WO 2001-IB2341	W	20011206
MX 2003PA06887	A	20031113	MX 2003-PA6887		20030730
			US 2001-265492P	P	20010131
			WO 2001-IB2341	W	20011206

OS  
GI



I



II

AB The title compds. [I; g = 0-1; j = 0-1; provided that when j = 0, n must be 2; k = 0-1; m = 0-2; n = 1-2; W1 = 0, SOT (t = 0-2), NR3; W2 = OCR9R10, or absent; Y = CR1, NOK (k = 0-1); R9, R10 = H, F, CF3, etc.; or R9 and R10 are taken together, but only in the case where m = 1, to form a spiro moiety; R7, R8 have the same meaning as R9, R10 except that one of them must be H; R1, R2 = H, F, Cl, etc.; R3 = H, alkyl, Ph, etc.; R4-R6 = H, F, Cl, etc.; Q1 = Ph, benzodioxyl, etc.; Q2 = biaryl moiety], useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructive pulmonary disease, were prepared E.g., a multi-step synthesis of the amide II, starting from Me 3-bromobenzoate and 4-formylbenzeneboronic acid, was given. Compds. I showed anti-inflammatory activity at 0.0001  $\mu$ M to 20.0  $\mu$ M in whole blood assay for LTE4.

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN  
TI LTB4 antagonism  
AN 2001:360988 CAPLUS  
DN 136:47743  
TI LTB4 antagonism  
AU Jennewein, H. M.; Anderskewitz, R.; Meade, C. J.; Pairet, M.; Birke, F.  
CS Department of Pulmonary Research, Boehringer Ingelheim KG, Ingelheim, Germany  
SO Progress in Respiratory Research (2001), 31(New Drugs for Asthma, Allergy and COPD), 121-125  
CODEN: PRRRAE; ISSN: 1422-2140  
PB S. Karger AG  
DT Journal; General Review  
LA English  
AB A review is given. LTB4 is one of the most important mediators for neutrophil granulocyte survival, trafficking, and activation. A major

role was proposed in the pathophysiol. of respiratory diseases characterized by a neutrophilic-type of inflammation, such as chronic bronchitis, severe asthma, and cystic fibrosis. Elevated LTB4 levels were found in sputum and BAL fluid of patients with COPD, cystic fibrosis, and severe asthma. This constitutes the medical rationale for testing LTB4 antagonists in certain forms of asthma and in COPD. A 1st clin. trial has demonstrated that an LTB4 antagonist could reduce the number of BAL fluid neutrophils in patients with mild asthma. Several LTB4 antagonists are known, the most important ones being CP 195543, SC 53228, CGS 25019C, ONO 4057, LY 293111 Na, and BIIL 284 BS. All these compds. are specific LTB4 antagonists, but they differ with respect to efficacy and pharmacokinetic properties. Their clin. evaluation is ongoing.

RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD.  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN  
TI Low-adenosine antisense oligonucleotide agents, compositions, kits and treatments for respiratory disorders  
AN 2000:133697 CAPLUS  
DN 132:203144  
TI Low-adenosine antisense oligonucleotide agents, compositions, kits and treatments for respiratory disorders  
IN Nyce, Jonathan W.  
PA East Carolina University, USA  
SO PCT Int. Appl., 1343 pp.  
CODEN: PIXXD2

DT Patent  
LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000009525	A2	20000224	WO 1999-US17712	19990803
WO 2000009525	A3	20000518		
W: AU, CA, CN, MX, RU, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2333901	A1	20000224	US 1998-95212P	P 19980803
			CA 1999-2333901	19990803
			US 1998-95212P	P 19980803
			WO 1999-US17712	W 19990803
AU 9953374	A1	20000306	AU 1999-53374	19990803
			US 1998-95212P	P 19980803
			WO 1999-US17712	W 19990803
EP 1102786	A2	20010530	EP 1999-939006	19990803
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
			US 1998-95212P	P 19980803
			WO 1999-US17712	W 19990803

OS MARPAT 132:203144

AB A composition comprises a nucleic acid comprising an oligo antisense to a target such as polypeptide(s) associated with an ailment afflicting lung airways, genes and mRNAs encoding them, genomic and mRNA flanking regions, intron and exon borders and all regulatory and functionally related segments of the genes and mRNAs encoding the polypeptides, their salts and mixts. Various formulations contain a requisite carrier, and optionally other additives and biol. active agents. The agent of the invention may be prepared by selecting a target gene(s), genomic flanking region(s), RNA(s) and/or polypeptide(s) associated with a disease(s) or condition(s) afflicting lung airways, obtaining the sequence of the mRNA(s) corresponding to the target gene(s) and/or genomic flanking region(s), and/or RNAs encoding the target polypeptide(s), selecting at least one segment of the mRNA which may be up to 60% free of thymidine (T) and synthesizing one or more antisense oligonucleotide(s) to the mRNA segments

which are free of adenosine (A) by substituting a universal base for A when present in the oligonucleotide. The agent may be prepared by selection of target nucleic acid sequences with GC running stretches, which have low T content, and by optionally replacing A in the antisense oligonucleotides with a universal base. The agent, composition and formulations are used for prophylactic, preventive and therapeutic treatment of ailments associated with impaired respiration, allergy(ies) and/or inflammation, such as pulmonary vasoconstriction, inflammation, allergies, asthma, impeded respiration, lung pain, cystic fibrosis, bronchoconstriction, pulmonary hypertension and bronchoconstriction, chronic bronchitis, emphysema, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), ischemic conditions including ischemia itself, and cancers such as leukemias, lymphomas, carcinomas, and the like, e.g. colon cancer, breast cancer, pancreatic cancer, lung cancer, hepatocellular carcinoma, kidney cancer, melanoma, hepatic metastasis, etc., as well as all types of cancers with may metastasize or have metastasized to the lung(s), including breast and prostate cancer. The present treatment is suitable for administration in combination with other treatments, e.g. before, during and after other treatments, including radiation, chemotherapy, antibody therapy and surgery, among others. The present agent is effectively administered preventatively, prophylactically or therapeutically by itself for conditions without known therapies, or as a substitute for, or in conjunction with, other therapies exhibiting undesirable side effects. The treatment of this invention may be administered directly into the respiratory system of a subject, so that the agent has direct access to the airways and the lungs. The invention is exemplified with specificity and pharmacokinetic studies using phosphorothioated antisense oligonucleotides targeted to the adenosine receptors A1, A2a, A2b, and A3.

=> logoff hold

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	30.84	31.05
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-2.34	-2.34

SESSION WILL BE HELD FOR 120 MINUTES  
STN INTERNATIONAL SESSION SUSPENDED AT 10:08:38 ON 06 AUG 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*  
SESSION RESUMED IN FILE 'CAPLUS' AT 10:51:40 ON 06 AUG 2007  
FILE 'CAPLUS' ENTERED AT 10:51:40 ON 06 AUG 2007  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	30.84	31.05
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION



CA SUBSCRIBER PRICE

-2.34

-2.34

=> d his

(FILE 'HOME' ENTERED AT 10:02:57 ON 06 AUG 2007)

FILE 'CAPLUS' ENTERED AT 10:03:17 ON 06 AUG 2007

L1 35 COPD AND ASTHMA AND (CYSTIC FIBROSIS) AND BRONCHITIS  
L2 30339 LIPOXYGENASE OR LEUKOTRIENE  
L3 10 L1 AND L2  
L4 82863 DIENE  
L5 0 L3 AND L4  
L6 226 L2 AND L4

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

30.84

31.05

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-2.34

-2.34

FILE 'REGISTRY' ENTERED AT 10:51:56 ON 06 AUG 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 3 AUG 2007 HIGHEST RN 944028-34-6

DICTIONARY FILE UPDATES: 3 AUG 2007 HIGHEST RN 944028-34-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Documents and Settings\PZucker\My Documents\Examination Auxillary files\10715377\10715377 saturated lniker.str



chain nodes :

7 8 9 10 11

ring nodes :

1 2 3 4 5 6

chain bonds :

5-7 7-8 8-9 8-11 9-10

ring bonds :  
 1-2 1-6 2-3 3-4 4-5 5-6  
 exact/norm bonds :  
 8-9 8-11  
 exact bonds :  
 5-7 7-8 9-10  
 normalized bonds :  
 1-2 1-6 2-3 3-4 4-5 5-6

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS  
 11:CLASS

L7 STRUCTURE UPLOADED

=> d 17

L7 HAS NO ANSWERS

L7 STR



Structure attributes must be viewed using STN Express query preparation.

=> search 17 sss sam

SAMPLE SEARCH INITIATED 10:52:18 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 344 TO ITERATE

100.0% PROCESSED 344 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 5768 TO 7992

PROJECTED ANSWERS: 1520 TO 2760

L8 50 SEA SSS SAM L7

=> dscan

0 DSCAN

L9

0 DSCAN

=> d scan 17


L7 HAS NO ANSWERS

=> d scan 18

L8 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN Butanediamide, N1-[(1S)-1-[[4-[[[(iminophenylmethyl)amino]methyl]phenyl]methyl]-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)-N4-(phenylmethoxy)-3-(3-phenylpropyl)-, monohydrochloride, (2R,3S)- (9CI)

Absolute stereochemistry.




HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):10

IN 5-Hexenoic acid, 3-[(hydroxyamino)carbonyl]-2-(2-methylpropyl)-6-phenyl-,  
2-[[3-(diethylamino)propyl]sulfonyl]-2-(2-methylpropyl)hydrazide,  
(2R,3S,5E)- (9CI)

CI COM


Absolute stereochemistry.  
Double bond geometry as shown.



L8 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 1-Pyrrolidinebutanamide,  $\beta$ -[3-[3,5-bis(trifluoromethyl)phenyl]propyl]-  
N, $\alpha$ -dihydroxy- $\gamma$ -oxo-, ( $\alpha$ S, $\beta$ R)- (9CI)


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L8 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
 IN Butanediamide, N1-[(1S)-1-[[[(1,1-diphenylethyl)amino]carbonyl]-2,2-dimethylpropyl]-N4-hydroxy-2-(3-phenylpropyl)-, (2R)- (9CI)  
 MF C33 H41 N3 O4


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L8 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
 IN 1H-1,2,3-Triazole-1-acetic acid, 2-[(2R,3S)-3-[(hydroxyamino)carbonyl]-2-(2-methylpropyl)-1-oxo-6-phenylhexyl]-1-[(2S)-2-methylbutyl]hydrazide (9CI)  
 MF C26 H40 N6 O4


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L8 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
 IN 5-Hexenoic acid, 3-[(hydroxyamino)carbonyl]-2-(2-methylpropyl)-6-phenyl-,  
 2-[(2S)-2,4-diamino-1,4-dioxobutyl]-2-(2-methylpropyl)hydrazide,  
 (2R,3S,5E)-(9CI)  
 MF C25 H39 N5 O5  
 CI COM


Absolute stereochemistry.  
 Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L8 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
 IN Benzenehexanamide, ε-hydroxy-N-(1-methoxy-1-methylethoxy)-4-[[4-(  
 (methylthio)phenyl]ethynyl]-, (εR)-(9CI)  
 MF C25 H31 N O4 S

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L8 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
 IN 7-Octenamide, N-hydroxy-8-(2-naphthalenyl)-  
 MF C18 H21 N O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L8 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
 IN [1,1'-Biphenyl]-4-hexanamide, 4'-chloro-N,ε-dihydroxy-ε-(3-methoxy-1-propynyl)- (9CI)  
 MF C22 H24 Cl N O4



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L8 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
 IN L-Phenylalanine, N-[(2S)-3-[(hydroxyamino)carbonyl]-2-(2-methylpropyl)-1-oxo-6-phenylhexyl]-4-[[[(1-iminoethyl)amino]methyl]-, methyl ester (9CI)  
 MF C30 H42 N4 O5  
 CI COM


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L8 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
 IN 4-Thiomorpholinebutanamide, β-[3-(4-ethoxyphenyl)propyl]-N,α-  
 dihydroxy-γ-oxo-, (αS,βR)- (9CI)  
 MF C19 H28 N2 O5 S

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
5.85	36.90

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE ENTRY	TOTAL SESSION
0.00	-2.34

CA SUBSCRIBER PRICE

FILE 'CAPLUS' ENTERED AT 10:53:20 ON 06 AUG 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 Aug 2007 VOL 147 ISS 7  
FILE LAST UPDATED: 5 Aug 2007 (20070805/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> l8

L10 26 L8

=> d his

(FILE 'HOME' ENTERED AT 10:02:57 ON 06 AUG 2007)

FILE 'CAPLUS' ENTERED AT 10:03:17 ON 06 AUG 2007

L1 35 COPD AND ASTHMA AND (CYSTIC FIBROSIS) AND BRONCHITIS  
L2 30339 LIPOXYGENASE OR LEUKOTRIENE  
L3 10 L1 AND L2  
L4 82863 DIENE  
L5 0 L3 AND L4  
L6 226 L2 AND L4

FILE 'REGISTRY' ENTERED AT 10:51:56 ON 06 AUG 2007

L7 STRUCTURE UPLOADED  
L8 50 SEARCH L7 SSS SAM  
L9 0 DSCAN

FILE 'CAPLUS' ENTERED AT 10:53:20 ON 06 AUG 2007

L10 26 L8

=> l2 and l10

L11 0 L2 AND L10

=> l1 and l11

L12 0 L1 AND L11

=> l1 and l10

L13 0 L1 AND L10

=> logoff hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.94	37.84
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-2.34

SESSION WILL BE HELD FOR 120 MINUTES  
STN INTERNATIONAL SESSION SUSPENDED AT 10:54:22 ON 06 AUG 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x



LOGINID:SSSPTA1623PAZ

PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*  
SESSION RESUMED IN FILE 'CAPLUS' AT 10:55:32 ON 06 AUG 2007  
FILE 'CAPLUS' ENTERED AT 10:55:32 ON 06 AUG 2007  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.94	37.84
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-2.34

=> prostaglandin  
71302 PROSTAGLANDIN  
44741 PROSTAGLANDINS  
L14 82054 PROSTAGLANDIN  
(PROSTAGLANDIN OR PROSTAGLANDINS)

=> d his

(FILE 'HOME' ENTERED AT 10:02:57 ON 06 AUG 2007)

FILE 'CAPLUS' ENTERED AT 10:03:17 ON 06 AUG 2007

L1 35 COPD AND ASTHMA AND (CYSTIC FIBROSIS) AND BRONCHITIS  
L2 30339 LIPOXYGENASE OR LEUKOTRIENE  
L3 10 L1 AND L2  
L4 82863 DIENE  
L5 0 L3 AND L4  
L6 226 L2 AND L4

FILE 'REGISTRY' ENTERED AT 10:51:56 ON 06 AUG 2007

L7 STRUCTURE UPLOADED  
L8 50 SEARCH L7 SSS SAM  
L9 0 DSCAN

FILE 'CAPLUS' ENTERED AT 10:53:20 ON 06 AUG 2007

L10 26 L8  
L11 0 L2 AND L10  
L12 0 L1 AND L11  
L13 0 L1 AND L10  
L14 82054 PROSTAGLANDIN

=> hydroxamic  
7264 HYDROXAMIC  
1 HYDROXAMICS  
L15 7265 HYDROXAMIC  
(HYDROXAMIC OR HYDROXAMICS)

=> l14(l)l15  
L16 10 L14(L)L15

=> d l16 1-10 ti

L16 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN  
TI Parallel synthesis and in vitro activity of novel anthranilic  
hydroxamate-based inhibitors of the prostaglandin H2 synthase peroxidase  
activity

L16 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN  
TI Histone Deacetylase Inhibitors Suppress the Induction of c-Jun and Its  
Target Genes Including COX-2

L16 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN  
 TI Design, parallel chemical synthesis and in vitro characterization of novel hydroxamate-based prostaglandin H2 synthase inhibitors

L16 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN  
 TI Aromatic hydroxamic acids and hydrazides as inhibitors of the peroxidase activity of prostaglandin H2 synthase-2

L16 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN  
 TI A process for the preparation of prostaglandin F analogs

L16 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN  
 TI Tepoxalin, a novel dual inhibitor of the prostaglandin-H synthase cyclooxygenase and peroxidase activities

L16 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN  
 TI Preparation and formulation of 7-oxabicycloheptane substituted hydroxamic acid prostaglandin analogs useful in treatment of thrombotic disease

L16 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN  
 TI Nonsteroidal antiinflammatory compounds to treat inflammation

L16 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN  
 TI A new class of irreversible inhibitors of leukotriene biosynthesis


L16 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN  
 TI Hydroxamic acid derivatives of prostaglandins

=> d l16 10 ti fbib abs

L16 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN  
 TI Hydroxamic acid derivatives of prostaglandins  
 AN 1977:189308 CAPLUS  
 DN 86:189308  
 TI Hydroxamic acid derivatives of prostaglandins  
 IN Aries, Robert  
 PA Fr.  
 SO Fr. Demande, 6 pp.  
 CODEN: FRXXBL  
 DT Patent  
 LA French  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2290425	A1	19760604	FR 1974-36785	19741106
	FR 2290425	B3	19770805	FR 1974-36785	A 19741106

GI



I

AB PGF2 alkyl esters were treated with HONH2.HCl and Na alkoxides to give PGF hydroxamic acids I (R = OH, R1 = H) and I (R = H, R1 = OH).

=> d 116 1-9 ti fbib abs

L16 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

TI Parallel synthesis and in vitro activity of novel anthranilic hydroxamate-based inhibitors of the prostaglandin H2 synthase peroxidase activity

AN 2005:1071789 CAPLUS

DN 144:22699

TI Parallel synthesis and in vitro activity of novel anthranilic hydroxamate-based inhibitors of the prostaglandin H2 synthase peroxidase activity

AU Lee, Jean; Chubb, Anthony J.; Moman, Edelmiro; McLoughlin, Brian M.; Sharkey, Caroline T.; Kelly, John G.; Nolan, Kevin B.; Devocelle, Marc; Fitzgerald, Desmond J.

CS Centre for Synthesis and Chemical Biology, Department of Pharmaceutical and Medicinal Chemistry, Royal College of Surgeons in Ireland, Dublin, 2, Ire.

SO Organic & Biomolecular Chemistry (2005), 3(20), 3678-3685

CODEN: OBCRAK; ISSN: 1477-0520

PB Royal Society of Chemistry

DT Journal

LA English

OS CASREACT 144:22699

AB Currently available non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin are directed at the cyclooxygenase (COX) site, but not the peroxidase (POX) activity of prostaglandin H2 synthase (PGHS). They are thus unable to inhibit the free-radical induced tissue injury associated with PGHS peroxidase activity, which can occur independently of the COX site. A lead compound, anthranilohydroxamic acid (AHA) was found to have significant PGHS-POX inhibitory activity (IC50 = 72 µM). To define the critical parameters for PGHS-POX inhibition, 29 AHA derivs., synthesized from their acid precursors, using solid phase synthesis, were investigated. In vitro anal. demonstrated a ten-fold improvement in inhibition with 3,5-diiodoanthranilohydroxamic acid (IC50 = 7 µM).

RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

TI Histone Deacetylase Inhibitors Suppress the Induction of c-Jun and Its Target Genes Including COX-2

AN 2005:1011798 CAPLUS

DN 143:278693

TI Histone Deacetylase Inhibitors Suppress the Induction of c-Jun and Its Target Genes Including COX-2

AU Yamaguchi, Kentaro; Lantowski, Agnieszka; Dannenberg, Andrew J.; Subbaramaiah, Kotha

CS Department of Medicine, Weill Medical College of Cornell University, New York, NY, 10021, USA

SO Journal of Biological Chemistry (2005), 280(38), 32569-32577

CODEN: JBCHA3; ISSN: 0021-9258

PB American Society for Biochemistry and Molecular Biology

DT Journal

LA English

AB Cyclooxygenase-2 (COX-2) is considered to be a target for anticancer therapy. Histone deacetylase (HDAC) inhibitors exhibit antitumor activity, but the mechanisms of action are incompletely understood. The authors investigated whether HDAC inhibitors blocked AP-1-mediated activation of COX-2 transcription. Trichostatin A and suberoylanilide hydroxamic acid, two structurally related inhibitors of HDAC activity, blocked AP-1-mediated induction of COX-2 expression and prostaglandin E2 biosynthesis. Chromatin immunopptn. assays

indicated that HDAC inhibitors suppressed c-Jun binding to the COX-2 promoter and thereby blocked transcription. The observed reduction in binding reflected reduced levels of c-Jun. HDAC inhibitors suppressed the induction of c-jun transcription by blocking the recruitment of the preinitiation complex (RNA polymerase II and TFIIB) to the c-jun promoter. HDAC3 but not HDAC1 or HDAC2 was required for AP-1-mediated stimulation of c-jun expression. Because HDAC inhibitors suppressed the induction of c-jun gene expression, resulting in reduced COX-2 transcription, it was important to determine whether other known AP-1 target genes were also modulated. Cyclin D1 and collagenase-1 are AP-1-dependent genes that have been implicated in carcinogenesis. HDAC inhibitors suppressed the induction of both cyclin D1 and collagenase-1 transcription by inhibiting the binding of c-Jun to the resp. promoters. Taken together, these results suggest that HDAC inhibitors block the induction of c-jun transcription by inhibiting the recruitment of the preinitiation complex to the c-jun promoter. This led, in turn, to reduced expression of several activator protein-1-dependent genes (COX-2, cyclin D1, collagenase-1). These findings provide new insights into the mechanisms underlying the antitumor activity of HDAC inhibitors.

RE.CNT 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN  
TI Design, parallel chemical synthesis and in vitro characterization of novel hydroxamate-based prostaglandin H2 synthase inhibitors  
AN 2005:739805 CAPLUS  
TI Design, parallel chemical synthesis and in vitro characterization of novel hydroxamate-based prostaglandin H2 synthase inhibitors  
AU Lee, Jean  
CS Department of Pharmaceutical and Medicinal Chemistry, Department of Pharmacy, Centre for Synthesis and Chemical Biology, Royal College of Surgeons in Ireland, Dublin, N/A, Ire.  
SO Abstracts of Papers, 230th ACS National Meeting, Washington, DC, United States, Aug. 28-Sept. 1, 2005 (2005), MEDI-294 Publisher: American Chemical Society, Washington, D. C.  
CODEN: 69HFCL  
DT Conference; Meeting Abstract; (computer optical disk)  
LA English  
AB Prostaglandin H2 synthase (PGHS), the first enzyme in the biotransformation of arachidonic acid to prostaglandins, has two active sites, a cyclooxygenase (COX), the target of aspirin, and a spatially and functionally distinct peroxidase (POX). The POX activity is independent of the COX activity, however the reverse does not hold. Inhibitors of the POX activity are of potential therapeutic value as unchecked peroxidase activity, leading to free radicals, contribute to disease progression despite NSAID administration. Aspirin irreversibly inhibits COX by acetylating a serine residue in the active site. Recently, we have produced a series of acetylating compds., including triacetylsalicylhydroxamic acid (TriACSHA), a more potent irreversible acetylating agent than aspirin and based on a salicylhydroxamic acid scaffold. Similarly, recent work carried out in our labs. has shown that anthranilic hydroxamic acid (AHA) is able to inhibit the peroxidase activity of PGHS. The presence of the hydroxamic acid group is essential as the carboxylic analog has a significant reduced inhibitory activity. A library of 30 AHA derivs., displaying various substituents on the aromatic ring, was synthesized by parallel synthesis. Four potent peroxidase inhibitors with IC50's in the low  $\mu$ M range have been identified. Structure-Activity Relationships are being investigated, looking at the other randomisation points on this AHA core scaffold.

L16 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN  
TI Aromatic hydroxamic acids and hydrazides as inhibitors of the peroxidase activity of prostaglandin H2 synthase-2  
AN 2004:819373 CAPLUS  
DN 142:19059

TI Aromatic hydroxamic acids and hydrazides as inhibitors of the peroxidase activity of prostaglandin H2 synthase-2

AU Ouellet, Marc; Aitken, Susan M.; English, Ann M.; Percival, M. David

CS Department of Biochemistry and Molecular Biology, Merck Frosst Centre for Therapeutic Research, Pointe-Claire-Dorval, QC, H9R 4P8, Can.

SO Archives of Biochemistry and Biophysics (2004), 431(1), 107-118  
CODEN: ABBIA4; ISSN: 0003-9861

PB Elsevier

DT Journal

LA English

AB The cyclooxygenase activity of the bifunctional enzyme prostaglandin H2 synthase-2 (PGHS-2) is the target of non-steroidal anti-inflammatory drugs: Inhibition of the peroxidase activity of PGHS has been less studied. Using Soret absorption changes, the binding of aromatic hydroxamic acids to the peroxidase site of PGHS-2 was examined to investigate the structural determinants of inhibition. Typical of mammalian peroxidases, the Kd for benzhydroxamic acid (42 mM) is much greater than that for salicylhydroxamic acid (475 µM). Binding of the hydroxamic acid tepoxalin (25 µM) resulted in only minor Soret changes. However, tepoxalin is an efficient reducing co-substrate, indicating that it is an alternative electron donor rather than an inhibitor of the peroxidase activity. Aromatic hydrazides are metabolically activated inhibitors of peroxidases. 2-Naphthoic hydrazide (2-NZH) caused the time- and concentration-dependent inhibition of both PGHS-2 peroxidase and cyclooxygenase activities. H2O2 was required for the inactivation of both PGHS-2 activities and indomethacin (which binds at the cyclooxygenase site) did not affect the peroxidase inhibitory potency of 2-NZH. A series of aromatic hydrazides were found to be potent inhibitors of PGHS-2 peroxidase activity with IC50 values in the 6-100 µM range for 13 of the 18 hydrazides examined. Selective inhibition of PGHS-2 over myeloperoxidase and horseradish peroxidase isoenzyme C was increased by certain ring substitutions. In particular, a chloro group para to the hydrazide moiety increased the PGHS-2 selectivity relative to both myeloperoxidase and horseradish peroxidase isoenzyme C.

RE.CNT 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

TI A process for the preparation of prostaglandin F analogs

AN 1999:194119 CAPLUS

DN 130:252191

TI A process for the preparation of prostaglandin F analogs

IN Amburgey, Jack S., Jr.; Wos, John August; Delong, Mitchell Anthony; De, Biswanath; Dai, Haiyan George; Soper, David Lindsey

PA The Procter & Gamble Company, USA

SO PCT Int. Appl., 29 pp.  
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9912899	A1	19990318	WO 1998-US18595	19980904
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ, DE, DE, DK, DK, EE, EE, ES, FI, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				US 1997-58253P	P 19970909
	AU 9893058	A	19990329	AU 1998-93058	19980904
				US 1997-58253P	P 19970909

			WO 1998-US18595	W 19980904
ZA 9808416	A	20000322	ZA 1998-8416	19980915
			WO 1998-US18595	W 19980904

OS CASREACT 130:252191; MARPAT 130:252191

GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB A process for preparing title compds. I (R1 = CO<sub>2</sub>H, C(O)NHOH, CO<sub>2</sub>R<sub>5</sub>, CH<sub>2</sub>OH, S(O)<sub>2</sub>R<sub>5</sub>, C(O)NHR<sub>5</sub>, C(O)NHS(O)R<sub>5</sub>, or tetrazole where R<sub>5</sub> = alkyl, heteroalkyl, carbocyclic or heterocyclic aliphatic ring, aromatic or heteroarom. ring; R<sub>2</sub> = H, alkyl; each R<sub>3</sub> is independently H, alkyl, alkoxy, haloalkyl, carbocyclic or heterocyclic aliphatic ring, aromatic or heteroarom. ring; Y = NR<sub>4</sub>, S, S(O), S(O)<sub>2</sub>, O or a bond provided that no carbon has more than one heteroatom attached to it, characterized in that R<sub>4</sub> = H, alkyl, acyl; p is from 0-5, q is from 0-5, and p + q is from 0-5 provided when Y is a bond p is at least 1; Z = H, Me, carbocyclic or heterocyclic aliphatic ring, aromatic or heteroarom. ring, provided when Y is S, S(O) or S(O)<sub>2</sub> Z is not H) was accomplished via intermediates II (R<sub>6</sub> = carboxylic acid, carboxylic acid ester, comprising a saturated or unsatd. C1-C8 alkyl, a carbocyclic ring, a hydroxamic acid, hydroxymethyl, sulfonic acid, sulfonyl ester, sulfonyl amide and tetrazole; the two R<sub>7</sub> form a 5- or 6-membered monocyclic aliphatic oxaheterocycle or a 8 to 12 member bicyclic aliphatic heterocycle), or a salt or protected form thereof. The preparation of II comprises (a) reacting a Corey aldehyde with an activated diol or two equivalent of an activated monohydric alc. to form an acetal; (b) deprotection, of the acetal deriv of step (a) to form a hydroxy acetal; (c) optionally reprotecting the hydroxy acetal of step (b); (d) reducing (b) or (c) to provide a lactol derivative; and (e) condensing the lactol derivative of step (d) with a phosphonium salt to form the intermediate acetal. Thus tetranor prostaglandin Fl $\alpha$  III was prepared in 8 steps from Corey aldehyde IV via the acetal intermediate V.

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN

TI Tepoxalin, a novel dual inhibitor of the prostaglandin-H synthase cyclooxygenase and peroxidase activities

AN 1995:628939 CAPLUS

DN 123:102272

TI Tepoxalin, a novel dual inhibitor of the prostaglandin-H synthase cyclooxygenase and peroxidase activities

AU Tam, Susanna S. C.; Lee, Daniel H. S.; Wang, Elizabeth Y.; Munroe, Donald G.; Lau, Catherine Y.

CS Discovery Res., R. W. Johnson Pharmaceutical Res. Inst., Don Mills, ON, M3C 1L9, Can.

SO Journal of Biological Chemistry (1995), 270(23), 13948-55  
CODEN: JBCHA3; ISSN: 0021-9258

PB American Society for Biochemistry and Molecular Biology

DT Journal


LA English

AB Prostaglandin-H synthase-1, the rate-limiting enzyme in prostaglandin synthesis, has both cyclooxygenase (CO) and peroxidase (PO) activities. While most nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit only the CO activity, the authors describe an inhibitor, tepoxalin, that inhibits both the CO (IC<sub>50</sub> = 0.1  $\mu$ M) and the PO (IC<sub>50</sub> = 4  $\mu$ M) activities. Unlike many NSAIDs which are competitive inhibitors of CO, tepoxalin is a noncompetitive inhibitor of CO and its inhibitory effect on PO but not CO is reversed by excess heme. Moreover, inhibition of the PO activity by tepoxalin is not dependent on the enzymic turnover of the CO activity. The hydroxamic acid of tepoxalin

is responsible for the PO inhibition since a carboxylic acid derivative of tepoxalin retains full CO but not PO inhibition. The authors postulated that the hydroxamic group might confer the ability to inhibit PO on conventional CO inhibitors. This idea was supported by the observation that naproxen hydroxamic acid, but not naproxen showed PO inhibition. Furthermore, tepoxalin's carboxylic acid analog and naproxen each competitively relieved PO inhibition by their resp. hydroxamic acids. The intracellular activity of PO as monitored by the release of reactive oxygen species was also inhibited by both tepoxalin and naproxen hydroxamic acid. These observations suggest a strategy for the design of novel compds. to inhibit prostaglandin synthase PO. The therapeutic implications of these novel PO inhibitors are discussed.

L16 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN  
 TI Preparation and formulation of 7-oxabicycloheptane substituted hydroxamic acid prostaglandin analogs useful in treatment of thrombotic disease  
 AN 1988:492638 CAPLUS  
 DN 109:92638  
 TI Preparation and formulation of 7-oxabicycloheptane substituted hydroxamic acid prostaglandin analogs useful in treatment of thrombotic disease  
 IN Nakane, Masami; Reid, Joyce  
 PA E. R. Squibb and Sons, Inc., USA  
 SO U.S., 19 pp.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN. CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4734425	A	19880329	US 1986-920006	19861017
	GB 2196338	A	19880427	GB 1987-22764	19870928
	GB 2196338	B	19900808		
				US 1986-920006	A 19861017
	FR 2605319	A1	19880422	FR 1987-13867	19871007
	FR 2605319	B1	19891222		
				US 1986-920006	A 19861017
	DE 3735128	A1	19880421	DE 1987-3735128	19871016
				US 1986-920006	A 19861017
	JP 63104981	A	19880510	JP 1987-262559	19871017
			US 1986-920006	A 19861017	
OS	CASREACT 109:92638; MARPAT 109:92638				
GI					




AB Title compds. I (A = CH:CH, CH<sub>2</sub>CH<sub>2</sub>; M = 1-5; R = HO<sub>2</sub>C, CO<sub>2</sub>alkyl, CO<sub>2</sub> alkali metal, CO<sub>2</sub>polyhydroxyamine salt, HOCH<sub>2</sub>, tetrazolyl, R<sub>4</sub>R<sub>5</sub>NCO, R<sub>4</sub>, R<sub>5</sub> = H, alkyl, HO, alkoxy, aryl, at least 1 of R<sub>4</sub> and R<sub>5</sub> being other than HO or alkoxy; R<sub>1</sub>, R<sub>2</sub> = H, HO, provided that 1 of R<sub>1</sub> is HO, the other is H; o = 1-12, R<sub>3</sub> = H, alkyl, alkenyl, arylamine, etc.), their salts and stereoisomers, which are cardiovascular agents useful, e.g., in treatment of thrombotic disease (no data) were prepared Me [1S-[1 $\alpha$ ,2 $\beta$ (5Z),3 $\beta$ ,4 $\alpha$ ]]-7-[(3-(aminomethyl)-7-oxabicyclo[2.2.1]hept-2-yl-5-heptenoate prepared in 5 steps from hydroxylamine O-tetrahydropyran ether and Me(CH<sub>2</sub>)<sub>5</sub>CON(OH)CH<sub>2</sub>CO<sub>2</sub>H dissolved

in THF in Ar atmospheric was treated with DCC to give [1S-[1 $\alpha$ ,2 $\beta$ (5Z),3 $\beta$ ,4 $\alpha$ ]]-I (A = CH:CH; n = 3; R = MeO<sub>2</sub>C; R<sub>1</sub> = HO; q = 1; R<sub>2</sub> = H; R<sub>3</sub> = Me(CH<sub>2</sub>)<sub>4</sub>).

L16 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN  
 TI Nonsteroidal antiinflammatory compounds to treat inflammation  
 AN 1986:400628 CAPLUS  
 DN 105:628  
 TI Nonsteroidal antiinflammatory compounds to treat inflammation  
 IN Smerbeck, Richard V.; Pittz, Eugene P.  
 PA Warner-Lambert Co., USA  
 SO U.S., 4 pp.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4559328	A	19851217	US 1984-623271	19840621
	CA 1241919	A1	19880913	CA 1985-479481	19850418
				US 1984-623271	A 19840621
OS	MARPAT 105:628				
GI					



AB Antiinflammatory agents I (R<sub>1</sub> = OMe, CH<sub>2</sub>OH, CO<sub>2</sub>H, Ph, OH, hydroxamic acid; R<sub>2</sub> = H, OH, SH; R<sub>3</sub> = H, OH) are useful for the treatment of inflammation on mammals. Skin inflammation from UVB irradiation of guinea pigs showed severe blanching (blanching score 3) 1 h after topical application of p-hydroxydiphenyl (10  $\mu$ L of 3% solution in 90% DMSO as compared with moderate blanching (blanching score 2) with a 3% 2-hydroxybenzophenone control solution. Thus, the compds. inhibited prostaglandin production as indicated by the reduction of inflammation evidenced by blanching.

L16 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN  
 TI A new class of irreversible inhibitors of leukotriene biosynthesis  
 AN 1985:108686 CAPLUS  
 DN 102:108686  
 TI A new class of irreversible inhibitors of leukotriene biosynthesis  
 AU Corey, E. J.; Cashman, John R.; Eckrich, Thomas M.; Corey, David R.  
 CS Dep. Chem., Harvard Univ., Cambridge, MA, 02138, USA  
 SO Journal of the American Chemical Society (1985), 107(3), 713-15  
 CODEN: JACSAT; ISSN: 0002-7863  
 DT Journal  
 LA English  
 GI





AB 7-Thiaarachidonic acid (I) and 3 truncated analogs (II, III, and IV) were synthesized by a stereospecific method, along with the sulfoxides of I-III and the hydroxamic acid of III. I-IV were potent irreversible inhibitors of the 1st step in leukotriene biosynthesis, the conversion of arachidonate to 5-HPETE by the 5-lipoxygenase (5-LO) from RBL-1 cells in the presence of air. The rate consts. for the aerobic 5-LO deactivation by I-IV (min<sup>-1</sup> at 30°) were 0.63, 0.50, 0.43, and 0.39, resp. The sulfoxides of I-III were strictly competitive inhibitors of 5-LO. The 7-thia acids, I-III, were reversible, competitive inhibitors of the prostaglandin synthetase (arachidonate cyclooxygenase) from ram seminal vesicles. A mechanistic working hypothesis which accommodates the present facts on 5-LO is presented. The 7-thia-5,8(Z)-dienoic acids are exceptionally interesting for physiol. and therapeutic studies.

```
=> logtofdf hold
      0 LOGTOFDF
    42949 HOLD
    29154 HOLDS
    70995 HOLD
      (HOLD OR HOLDS)
L17      0 LOGTOFDF HOLD
      (LOGTOFDF(W) HOLD)
```

```
=> logoff hold
COST IN U.S. DOLLARS          SINCE FILE      TOTAL
                                ENTRY      SESSION
FULL ESTIMATED COST          45.85      82.75

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)  SINCE FILE      TOTAL
                                                ENTRY      SESSION
CA SUBSCRIBER PRICE          -7.80     -10.14
```

SESSION WILL BE HELD FOR 120 MINUTES  
STN INTERNATIONAL SESSION SUSPENDED AT 11:02:22 ON 06 AUG 2007